Annovis Bio

Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease

BERWYN, PA — In a recent breakthrough, Annovis Bio (NYSE: ANVS), a biopharmaceutical company, has successfully performed measurements of critical biomarkers in the plasma of Parkinson’s disease patients. Utilizing buntanetap, …

Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease Read More
Annovis Bio

Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases, recently announced a significant milestone in its clinical trial journey. The …

Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward Read More
Annovis Bio

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS)recently announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to continue as originally planned without …

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study Read More